Filing Analysis
Artiva Biotherapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026.
📋 Key Facts
- Report date: August 6, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes a press release (Exhibit 99.1) regarding financial results.
Artiva Biotherapeutics announced the expected date for its 2026 annual meeting of stockholders as September 8, 2026. The filing outlines specific deadlines for stockholder nominations and proposals to be considered at this meeting.
📋 Key Facts
- The 2026 Annual Meeting of stockholders is expected to be held on September 8, 2026.
- Stockholders must provide notice of intention to nominate directors or bring business by the close of business on August 1, 2026.
- Stockholder proposals for inclusion in proxy materials under Rule 14a-8 must also be received by August 1, 2026.
Artiva Biotherapeutics (ARTV) filed an 8-K on May 19, 2026 disclosing multiple simultaneous leadership changes effective May 18, 2026. CFO Thad Huston is departing effective May 22, 2026, with no replacement identified yet, while CEO Fred Aslan has been appointed as interim principal financial and accounting officer. Concurrently, Diego Miralles, M.D. resigned from the Board of Directors to assume the newly created role of President and Head of Research and Development.
🚩 Red Flags
- CFO departure with no successor identified — CEO serving as interim CFO/PAO creates governance and internal control risk for a clinical-stage biotech
- Multiple simultaneous executive changes (CFO out, President title reshuffled, new President/Head of R&D appointed) suggest organizational instability
- Miralles prior consulting relationship (April–May 2026) terminated immediately upon full-time hire raises questions about independence of the appointment process
- Board size reduced from 8 to 7 concurrent with the leadership reshuffling, reducing oversight capacity
- CEO dual-hatting as CFO is unusual for a Nasdaq-listed company and may raise concerns with institutional investors and auditors around segregation of duties
- Huston severance conditioned on non-revocation clause — implies potential legal risk if agreement is revoked within the 21-day window
📋 Key Facts
- CFO Thad Huston separating from the Company effective May 22, 2026; no replacement named — active CFO search underway
- CEO Fred Aslan, M.D. appointed as interim principal financial officer and principal accounting officer in addition to his CEO role
- Dr. Fred Aslan also resigned as President of the Company (a title he previously held) but retains CEO role and Board seat
- Diego Miralles, M.D. resigned from the Board of Directors (reducing board size from 8 to 7) and appointed President and Head of Research and Development
- Huston severance: ~$135,000 (3 months base salary) plus up to 9 months COBRA, conditioned on non-revocation within 21 days of Separation Date
- Miralles Offer Letter: $600,000 annual base salary, 45% target bonus, 232,500 stock options + 77,500 RSUs as inducement grants under 2025 Inducement Plan
- Miralles equity vests over 4 years: 25% on May 15, 2027, remainder over 3 years; granted under Nasdaq Rule 5635(c)(4) inducement exception
- Miralles had a prior consulting agreement with the Company (entered April 2026) that was terminated May 17, 2026 upon his full-time appointment
- Company is an emerging growth company listed on Nasdaq Global Market
- All departures stated as not resulting from disputes or disagreements with the Company
Artiva Biotherapeutics entered into an underwriting agreement to raise approximately $300 million through a public offering of common stock and pre-funded warrants. The company is issuing over 23.8 million shares and 2.1 million warrants to a group of underwriters led by Jefferies and Cantor Fitzgerald.
🚩 Red Flags
- Significant dilution to existing shareholders from the issuance of approximately 26 million new share equivalents.
📋 Key Facts
- Agreement to sell 23,871,526 shares of common stock at $11.52 per share.
- Agreement to sell 2,170,138 pre-funded warrants at $11.5199 per warrant with an exercise price of $0.0001.
- Total expected gross proceeds are approximately $300.0 million before expenses.
- Underwriters include Jefferies LLC, TD Securities (USA) LLC, and Cantor Fitzgerald & Co.
- The offering is expected to close on May 11, 2026.
- The offering was made pursuant to an effective registration statement on Form S-3 (File No. 333-289325).
Artiva Biotherapeutics announced positive initial Phase 2a clinical data for its lead candidate AlloNK in refractory rheumatoid arthritis (RA) and reached alignment with the FDA on a single Phase 3 registrational trial design. Concurrently, the company suspended its at-the-market (ATM) sales agreement with Leerink Partners.
🚩 Red Flags
- The timeline to a potential BLA submission is long, targeted for 2029.
- The current efficacy data is based on a very small sample size (13 patients with 6-month follow-up).
- Suspension of an ATM agreement often precedes a larger, dilutive underwritten public offering following positive news.
📋 Key Facts
- Reported a 50% ACR50 response rate at six months in refractory RA patients (n=13) who failed two or more prior biologic/targeted therapies.
- FDA aligned on a single Phase 3 registrational trial design involving approximately 150 patients with a 2:1 randomization.
- No instances of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) were reported in the safety dataset.
- Suspended the Sales Agreement with Leerink Partners LLC, effectively halting ATM equity sales for the time being.
- Phase 3 trial initiation is expected in H2 2026, with primary efficacy data in H2 2028 and a potential BLA submission in 2029.
- Estimated U.S. market for refractory RA patients who failed 2+ b/tsDMARDs is 150,000 to 200,000 patients.
Artiva Biotherapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 10, 2026.
📋 Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The announcement was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results is included as Exhibit 99.1.
- The company is classified as an emerging growth company.
Artiva Biotherapeutics has appointed Thad Huston as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective February 18, 2026. Mr. Huston brings over 30 years of experience from major biotech and pharma companies, including Galapagos NV and Kite Pharma.
📋 Key Facts
- Thad Huston (age 56) appointed as CFO effective February 18, 2026.
- Annual base salary set at $540,000 with a discretionary annual cash bonus target of 40%.
- Granted 220,000 restricted stock units (RSUs) as an inducement award, vesting over four years.
- Huston previously served as CFO and COO at Galapagos NV (2023-2025) and VP of Finance at Kite Pharma (2021-2023).
- Severance package includes 9 months of salary and COBRA for non-change-of-control termination, increasing to 12 months plus full bonus and 100% equity acceleration upon a change of control.
Artiva Biotherapeutics appointed Elaine Sorg as a Class I director effective February 18, 2026, with her term expiring at the 2028 annual meeting. Ms. Sorg is a veteran pharmaceutical executive with 35+ years of experience including senior leadership at AbbVie and Eli Lilly. This is a routine board appointment with standard non-employee director compensation.
📋 Key Facts
- Elaine Sorg appointed as Class I director on February 18, 2026, term expires at 2028 annual meeting
- 35+ years pharma experience; formerly SVP at AbbVie and President of AbbVie's U.S. commercial operations (Nov 2020 - Jan 2024)
- Currently a director of CSL Limited (global biopharma), Senior Advisor at Boston Consulting Group (since May 2024), and member of Galapagos Scientific Strategy Board (since Oct 2025)
- Annual cash retainer of $40,000 for board service
- Initial option grant of 27,500 shares (1/3 vested immediately, remainder monthly over 2 years)
- Automatic annual option grants of 13,750 shares vesting over 1 year
- All options vest in full upon a change in control
- No related-party transactions requiring disclosure under Item 404(a) of Reg S-K
- No arrangements or understandings with any person regarding her selection as director
Artiva Biotherapeutics entered into RSU exchange agreements with its CEO and COO to address 'underwater' stock options. The program exchanges out-of-the-money options for Restricted Stock Units (RSUs) with new vesting schedules to incentivize retention.
🚩 Red Flags
- Significant 'underwater' options indicate the company's stock price has fallen significantly below previous strike prices.
- Related-party transactions involving top executives (CEO and COO) to modify compensation structures.
- Potential dilution of existing shareholders through the issuance of new RSUs.
📋 Key Facts
- CEO Fred Aslan surrendered 869,136 shares of common stock in options (566,470 vested; 302,666 unvested).
- COO Jennifer Bush surrendered 84,877 shares of common stock in options (60,372 vested; 24,506 unvested).
- The exchange replaces underwater options with RSUs under the 2024 Equity Incentive Plan.
- RSU grants became effective on December 12, 2025.
- New RSU vesting for executives includes milestones in August 2026, November 2026, February 2027, and potentially extending to February 2029.
Artiva Biotherapeutics announced positive initial safety and translational data for its AlloNK (AB-101) therapy in combination with anti-CD20 antibodies for autoimmune diseases. The data shows deep B-cell depletion without significant adverse events or cytokine release syndrome in 32 treated patients.
🚩 Red Flags
- None identified in this filing; the report focuses on positive clinical safety and efficacy signals.
📋 Key Facts
- Data cutoff date: October 1, 2025.
- 32 patients treated across refractory RA, SjD, SSc, SLE, and LN using AlloNK plus anti-CD20 mAb (rituximab or obinutuzumab).
- No Grade 3+ treatment-emergent adverse events (TEAEs) or serious adverse events reported.
- No reports of cytokine release syndrome (CRS), neurotoxicity (ICANS), Graft-versus-Host Disease, or hypogammaglobulinemia.
- All 23 patients analyzed showed non-quantifiable peripheral CD19+ B-cell levels by Day 13.
- Planned milestone: Share clinical response data for >15 refractory RA patients in H1 2026.
Artiva Biotherapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting period: Quarter ended September 30, 2025.
- Filing date: November 12, 2025.
- The press release containing the actual financial data is attached as Exhibit 99.1.
Artiva Biotherapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings release issued on August 6, 2025.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025
- Filing date: August 6, 2025
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Artiva Biotherapeutics held its 2025 Annual Meeting of Stockholders on June 24, 2025. The meeting resulted in the election of a Class I director, ratification of KPMG LLP as independent auditors, and approval of an amendment to the 2024 Equity Incentive Plan.
🚩 Red Flags
- Proposal 3 (Equity Incentive Plan amendment) received significant 'Votes Against' (2,583,159), though it passed.
📋 Key Facts
- Annual Meeting held on June 24, 2025.
- Daniel Baker, Ph.D. elected as Class I director for a three-year term through 2028.
- KPMG LLP ratified as the principal independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Stockholders approved an amendment to the 2024 Equity Incentive Plan to increase authorized shares by 1,214,580 shares.
- Record date for voting was April 25, 2025, with 24,363,119 shares outstanding.
Artiva Biotherapeutics, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting period: Quarter ended March 31, 2025.
- Filing date: May 8, 2025.
- The press release containing the actual data is attached as Exhibit 99.1.
Artiva Biotherapeutics announced its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the release of these earnings via press release.
📋 Key Facts
- Report date: March 24, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes an announcement of financial results under Item 2.02
- Company is classified as an emerging growth company
Artiva Biotherapeutics, Inc. announced the appointment of Daniel Baker, Ph.D., to its Board of Directors and his appointment to the Clinical Strategy Committee on January 28, 2025.
📋 Key Facts
- Daniel Baker, Ph.D., appointed as a Class I director effective January 28, 2025.
- Dr. Baker appointed to the Clinical Strategy Committee; term expires at the 2025 annual meeting of stockholders.
- Clinical Strategy Committee members include Laura Bessen, M.D., Brian Daniels, M.D., and Laural Stoppel, Ph.D., with Diego Miralles, M.D., serving as chair.
- Dr. Baker to receive an annual cash retainer of $40,000 for Board service and $7,500 for Committee service.
- Grant of options to purchase 27,500 shares of common stock with a multi-year vesting schedule.
- Dr. Baker brings significant industry experience, including VP of Immunology R&D at Johnson & Johnson (Janssen/Centocor).
Artiva Biotherapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal notice of the release of quarterly earnings data.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Quarter ended September 30, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- The filing is an announcement of earnings under Item 2.02.
Artiva Biotherapeutics, Inc. announced the appointment of Alison Moore, Ph.D., to its Board of Directors as a Class III director and member of the Technical Operations Committee on October 21, 2024.
📋 Key Facts
- Appointment date: October 21, 2024
- Appointee: Alison Moore, Ph.D.
- Role: Class III director and member of the Technical Operations Committee
- Term: Expiring at the 2027 annual meeting of stockholders
- Compensation: $40,000 annual cash retainer for Board service; $15,000 annual cash retainer for Technical Operations Committee service
- Equity Grant: Option to purchase 27,500 shares of common stock (1/3 vested immediately, remainder vesting monthly over two years)
- Professional Background: CTO at Codexis Inc.; former CTO/EVP at Allogene Therapeutics; former SVP at Amgen; former Director at Genentech
Artiva Biotherapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. This is a routine earnings release filing.
📋 Key Facts
- The filing reports on the period ending June 30, 2024.
- Financial results were announced via press release on August 29, 2024.
- The company is classified as an 'emerging growth company'.
Artiva Biotherapeutics filed an 8-K to announce the amendment and restatement of its Certificate of Incorporation and Bylaws. These changes were made in connection with the closing of the company's initial public offering (IPO) on July 22, 2024.
📋 Key Facts
- The filing was triggered by the closing of an Initial Public Offering (IPO) on July 22, 2024.
- The Company filed an amended and restated Certificate of Incorporation with the Secretary of State of Delaware.
- The Company adopted amended and restated Bylaws effective immediately following the IPO closing.
- The company is classified as an 'emerging growth company'.